Prior Exposure to Lamivudine Increases Entecavir Resistance Risk in Chronic Hepatitis B Patients without Detectable Lamivudine Resistance

The efficacy of entecavir (ETV) treatment in chronic hepatitis B (CHB) patients who were exposed to lamivudine (LAM) but had no detectable LAM resistance (LAM-R) is not well evaluated. In this study, we aimed to evaluate whether the probability of developing genotypic resistance to ETV in LAM-expose...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lee, Jeong-Hoon, Cho, Yuri, Lee, Dong Hyeon, Lee, Minjong, Yoo, Jeong-ju, Choi, Won-mook, Cho, Young Youn, Lee, Yun Bin, Yu, Su Jong, Yoon, Jung-Hwan, Lee, Hyo-Suk, Kim, Yoon Jun
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2014
Gaiak:
Antiviral Agents
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3957876/
https://ncbi.nlm.nih.gov/pubmed/24395227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02483-13
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak